

FIGURE 1

BEST AVAILABLE COPY




FIGURE 2

PCT/CA2004/002084





FIGURE 3

DIANO - TOP	 ~	\$ 6	-	4	••	inter	•	253		9		1	#	elist.	•		1	2) (h	, , , , , , , , , , , , , , , , , , ,			 t		mir .	• .	2	***	Caronavirus Spike Protein
	tom	pro S	eicin	F-000	iQt		F2:65:1		Filt	1	æ	Page	34	A	FRAGE	,	RE T	·1		Pass	iP .	FRACE			Fèsc 1			
ment —		The Control	eriah	W an				4. ,	#*: 	20310		神士 第二十	F20G		ing.		•		or D	AND COMPANY OF THE PARTY OF THE	Fæs	· er s · er s · er s · er s · er s	2631	4.5 41 4-		ec 19		Commercius Spike Protein Commercius nucleoprotein

1 Furffled Virus

2 Infected Gall lyeals

FIGURE 4






FIGURE 5

SARS CoV mAb V_L alignme

FIGURE 6A

SARS CoV mAb V_H alignment

FIGURE 6 B

SARS-specific monoclonal antibodies, Heavy chains (VH), amino acid sequences

F26G3-VH

EVRLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVKQSHGKNLEWIGGINPNNGGTTYNQKFKG KATLTVDKSSNTAYMELRSLTSEDSAVYYCSRGDYGTSYGYFDVWGAGTTVTVSSAKTTAPSVYPL A

F26G7-VH

VELLESGTVLARPGASVKMSCEASGYTFTTYWMHWIKQRPGQGLEWIGAIYPGNSDTTYNQKFKGK AKLTAVTSTSTAYMELSSLTNEDSAVYYCTREGIPQLLRTMDYWGQGTSVTVSSAKTTPPSV

F26G9-VH

VQLLESGTVLARPGASVKMSCKASGYSFT SYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGK AKLTAVTSASTAYMELSSLTNEDSAVYYCTRSVYYGYGYFDVWGAGTTVTVSSAKTTPPSV

F26G10-VH

EVQLEESGTVLARPGASVKMSCKASGYSFTSYWMHWVKQRPGQGLDWIGAIYPENSDTSYNQKFKG KAKLTAVTSASTAYMEHSSLTNEDSAVYYCTRSVYYGYGYFDVWGAGTTVTVSSAKTTAPSVYPLA PVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQ SITCNVAHPASSTKVDKKIEPRVPTSQN

F26G18-VH

LVQLEESGTVLPRPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTNYNQKFKG RATLTAVTSTSTASMELSSLTNEDSAVYYCTRDGYGSLYYYAMDFWGQGTSVTVSSAKTTAPSVK

F26G19-VH

EVQLEESGTVLARPGASVKMSCKASGYTFTTYRMHWIKQRPGQGLEWIGAIYPGNSDTTYNQKFKD KAKLTAVTSTSSAYMELSSLTNEDSAVYFCTREGIPQLLRTLDYWGQGTSVTVSSAKTTAPSVYPL

F26G1-VH

EVQLEESGPGLVAPSQSLSITCTVSGFSLTNYDISWIRQPPGKGLEWLGIIWTGGGTSYNSAFMSR LSISKDNSKSQVFLKMNSLQTDDTAIYYCVRDRVYYFPMDYWGQGTSVTVSSAKTTAPSVYPLA

F26G6-VH

MEWSWVFLFLVATATDVHSQVQLQQPGAELVKPGASVKVSCKASGYTFTNYWIHWVKQRPGQGLEW IGEINPGNGRTNYNGNFMNKATLTVDKSSNTAYMQLSSLTSEDSAVYHCARLDYWGQGTTLTVSSA KTTPPSV

F26G8-VH

VQLLESGAELVKPGASVKVSCKASGYTFTSYWIHWVKQRPGQGLEWIGEINPSNGRTNYNGNFESK ATLTVDKSSNTAYMHLSSLTYEDSAVYHCTRLDYWGQGTTLTVSSAKTTAPSVYPLA

Neutralizing mAbs are in bold text.

FIGURE 7

SARS-specific monoclonal antibodies, Light chains (VL), amino acid sequences

F26G3-VL

DILMTQSPTSFAVSLGQRATISCRTSQSVSTSSYSYMHWYQQKPGQPPKLLIKYASNLESGVPARF SGSGSGSDFTLNIHPVEEGDTATYYCQHSWEIPCAFGGGTKLEIKRADAAPTVS

F26G7-VL

ELVMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASTLDSGVPKRFSGSR SGSDYSLTISSLESEDFADYYCLQYISYPWTFGGGTKLEIKRADAAPTVS

F26G9-VL

DILMTQSHKCMSTSVGDRVSITCKASQDVSTAVVWYQQKPGQFPKLLIYWASTRHTGVPDRFTGSG SGTDYTLTISSVQAEDLALYYCQQHYTTPYTFGGGTKLEIKRADAAPTVS

F26G10-VL

DILMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSG SGTDYTLTISSVQAEDLALYYCQQHYSTPYTFGGGTKLEIKRADAAPTVS

F26G18-VL

ELVMTQSPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHAGVPSRFSGSG SGTDYSLTISNLEQEDIATYFCQQGYTLPYTFGGGTKLEIKRADAAPTVSKGEFQHTGGRY

F26C19-VT

DILMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQEKPDGTIKRLIYAASTLDSGVPKRFSGSR SGSDYSLTISSLESEDFADYYCLQYVSYPWTFGGGTKLEIKRADAAPTV

F26G1-VL

ELVMTQSPVSITASRGEKVTITCRASSSISSNYLHWYQQKPGSSPKLLIYRTSILASGVLDTFSGS GSESSYTLTISCMQDEVAATYYCQQGSSSPPHVRRGDQAGNKTG

F26G6-VL

ELVMTQSPASLSVATGKKVTIRCISSTDIDDDMNWYQQKAGKPPKLLISEGNIFSPGVPSRFSSSG NGTDFVFTVENTLSEDVADNYCLQSDNMPFTFGSGTKLGIKRADAAPTVS

F26G8-VL

ELVMTQSPASLSVITGKKVTIRCISNTDIDDDLNWSQLKAGEPPKLLISEGNIFSPGVPSRFSSSG NGTDFVFTIENTLSEDVANNYCFQSDNMPFTFGSGTKLEIKRADAAPTVS

Neutralizing mAbs are in bold text.

FIGURE 8

SARS-specific monoclonal antibodies, Heavy chains (VH), nucleotide sequences

F26G3-VH

F26G7-VH

F26G9-VH

F26G10-VH

F26G18-VH

TTGGTGCAGCTGGAGGAGTCTGGGACTGTGTTGCCAAGGCCTGGGGCTTCAGTGAAGATGTCCTGC
AAGGCTTCTGGCTACACCTTTACCAGCTACTGGAT GCACTGGGTAAAACAGAGGCCTGGACAGGGT
CTGGAATGGATTGGCGCTATTTATCCTGGAAATAG TGATACTAACTACAACCAGAAGTTCAAGGGC
AGGGCCACACTGACTGCAGTCACATCCACCAGCAC TGCCTCCATGGAGCTCAGCAGCCTGACAAAT
GAGGACTCTGCGGTCTATTACTGTACAAGAGACGGCTATGGTAGCCTTTATTACTATGCTATGGAC
TTCTGGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACAACAGCCCCATCGGTCAAGGGC
GA

FIGURE 9-1

F26G19-VH

F26G1-VH

F26G6-VH

F26G8-VH

Neutralizing mAbs are in bold text.

FIGURE 9-2

SARS-specific monoclonal antibodies, Light chains (VL), nucleotide sequences

F26G3-VL

F26G7-VL

GTGCCAGATGTGAGCTCGTGATGACCCAGTCTCCATCCTCTTATCTGCCTCTCTGGGAGAAAGAG
TCAGTCTCACTTGTCGGGCAAGTCAGGAAATTAGTGGTTATTTAAGCTGGCTTCAGCAGAAACCAG
ATGGAACTATTAAACGCCTGATCTACGCCGCATCCACTTTAGATTCGGGTGTCCCAAAAAGGTTCA
GTGGCAGTAGGTCTGGGTCAGATTATTCTCTCACCATCAGCAGCCTTGAGTCTGAAGATTTTGCAG
ACTATTACTGTCTACAATATATTAGTTATCCGTGGACGTTCGGGGGAGGTACCAAGCTGGAAATCA
AACGGGCTGATGCTGCACCAACTGTATCC

F26G9-VL

GACATTCTGATGACCCAGTCTCACAAATGCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACC
TGCAAGGCCAGTCAGGATGTGAGTACTGCTGTAGTCTGGTATCAACAAAAACCAGGGCAATTTCCT
AAACTACTGATTTACTGGGCATCCACCCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGA
TCTGGGACAGATTATACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCACTTTATTACTGT
CAGCAACATTATACCACTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAACGGGCTGAT
GCTGCACCAACTGTATCC

F26G10-VL

GGGCCCAGCCGGCCGAGCTCGACATTCTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAG
GAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGAGTACTGCTGTAGCCTGGTATCAAC
AAAAACCAGGGCAATCTCCTAAACTACTGATTTACTGGGCATCCACCCGGCACACTGGAGTCCCTG
ATCGCTTCACAGGCAGTGGATCTGGGACAGATTATACTCTCACCATCAGCAGTGTGCAGGCTGAAG
ACCTGGCACTTTATTACTGTCAGCAACATTATAGCACTCCGTACACGTTCGGAGGGGGGACCAAGC
TGGAAATAAAACGGGCTGATGCTGCACCAACTGTATCC

F26G18-VL

F26G19-VL

FIGURE 10-1

F26G1-VL

F26G6-VL


GTGCCAGATGTGAGCTCGTGATGACCCAGTCTCCAGCATCCCTGTCCGTGGCTACAGGAAAAAAAG
TCACCATCAGATGCATAAGCAGCACTGACATTGATGATGATATGAACTGGTACCAGCAGAAGGCAG
GAAAACCTCCTAAACTCCTTATTTCAGAAGGCAATATTTTTAGTCCTGGAGTCCCATCCCGATTCT
CCAGCAGTGGCAATGGCACAGATTTTGTTTTTACAGTTGAAAACACGCTCTCAGAAGATGTTGCAG
ATAACTACTGTTTGCAAAGTGATAACATGCCATTCACGTTCGGCTCGGGGACAAAGTTGGGAATAA
AACGGGCTGATGCTGCACCAACTGTATCC

F26G8-VL


GTGCCAGATGTGAGCTCGTGATGACCCAGTCTCCAGCATCCCTGTCCGTGATTACAGGAAAAAAAG
TCACCATCAGATGCATAAGCAACACTGACATTGATGATGATTTTGAACTGGTCCCAGCTGAAGGCAG
GAGAACCTCCTAAACTCCTTATTTCAGAAGGCAATATTTTTAGTCCTGGAGTCCCATCCCGATTCT
CCAGCAGTGGCAATGGCACAGATTTTGTTTTTACAATTGAAAACACGCTCTCAGAAGATGTTGCAA
ATAACTACTGTTTCCAAAGTGATAACATGCCATTCACGTTCGGCTCGGGGACAAAGTTGGAAATAA
AACGGGCTGATGCTGCACCAACTGTATCC

Neutralizing mAbs are in bold text.


FIGURE 10-2



(A)




(B)



(C)

FIGURE 11






Figure 12




Figure 13

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record.

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.